Rapid Rx Quiz: Sexually Transmitted Infection Drug Treatments

Mary L. Windle, PharmD


November 18, 2022

Researchers reported on the results of the recent open-label DoxyPEP trial at the 24th International AIDS Conference. They found that among TGW and MSM who are taking HIV PrEP or are living with HIV, a single 200-mg dose of doxycycline PEP reduced the incidence of chlamydia, gonorrhea, and early syphilis by 65%.

The trial randomly assigned TGW and MSM who were on HIV PrEP or were living with HIV to either doxycycline or placebo within 72 hours of condomless sex. All participants had a history of chlamydia, gonorrhea, or early syphilis in the past year. The trial was stopped early after a planned interim analysis revealed that the doxycycline group had substantially fewer STIs than did the control group.

The researchers caution that the participants had a very high rate of new STIs and are a limited population.

Learn more about doxycycline.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.